Pharmacyte Biotech Inc. Financials
PMCB
All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | TTM | APR 2026 | APR 2025 | APR 2024 | APR 2023 | APR 2022 ~10.7:1 split |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| General & Administrative | $5 | $5 | $4 | $6 | $1 | $1 |
| Research & Development | $0 | $0 | $0 | $0 | $0 | $1 |
| Total Operating Expenses | $7 | $7 | $4 | $9 | $6 | $4 |
| Operating Income | -$7 | -$7 | -$4 | -$9 | -$6 | -$4 |
| Non-Operating | ||||||
| Net Interest Expense | – | – | – | – | $0 | -$0 |
| Other Non-Operating Income (Expense) | -$9 | -$13 | $35 | $9 | $2 | $0 |
| Income Tax Expense | – | $0 | $0 | $0 | $0 | $0 |
| Net Income | ||||||
| Net Income | -$16 | -$19 | $31 | $0 | -$4 | -$4 |
| Per Share Data | ||||||
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Basic) | -$2.08 | -$2.77 | $3.19 | -$1.80 | -$0.22 | -$0.27 |
| EPS (Diluted) | -$2.40 | -$2.77 | $3.19 | -$1.80 | -$0.22 | -$0.27 |
| Weighted Avg Shares (Basic) | 10.7M | 8.4M | 7.3M | 9.6M | 19.5M | 15.5M |
| Weighted Avg Shares (Diluted) | 10.7M | 8.4M | 7.3M | 9.6M | 19.5M | 15.5M |
| Shares Outstanding | 10.7M | 8.4M | 7.3M | 9.6M | 19.5M | 15.5M |
Pharmacyte Biotech (PMCB) financials: revenue, profit and margins
Pharmacyte Biotech (PMCB) generated about $0.00 in revenue and -$16 million in net income over the trailing twelve months, growing at roughly -68.9% a year. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
What is Pharmacyte Biotech's (PMCB) revenue?+
Pharmacyte Biotech generated about $0.00 in revenue over the trailing twelve months. Revenue has grown at roughly -68.9% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Pharmacyte Biotech profitable?+
Pharmacyte Biotech reported about -$16 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
How fast is Pharmacyte Biotech growing?+
Pharmacyte Biotech's revenue has compounded at roughly -68.9% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside PMCB's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 11 Sept 2026, covering the period ending 31 Jul 2026, as reported to the SEC. Data last refreshed 15 Sept 2026. How this is calculated.
Fiscal year ends Apr.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with PMCB
Spot a number that looks wrong? Check it in PMCB's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing PMCB
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.